For the diagnosis of BPDCN, the tumor should be negative for other myelomonocytic, NK, T, and B lineage markers (CD34, CD8, MPO, lysozyme, PAX5, CD20, CD79a, EBV, and T-cell receptor protein). The gene discussed is MPO; the disease is CD4+/CD56+ hematodermic neoplasm.